合并慢性肾脏病的心力衰竭患者的管理
慢性肾脏病在心力衰竭患者中常见,与高死亡率和发病率相关,长期透析患者更高。尽管一般人群心力衰竭的循证药物和器械治疗应用增加,但CKD患者并未受益。本综述讨论CKD中心力衰竭的患病率及肾脏替代、器械和药物治疗的证据。
要点
- β受体阻滞剂可改善所有CKD分期(包括透析)HFrEF患者结局。
- SGLT2抑制剂改善HFrEF合并CKD 3-4期(eGFR>20)患者死亡和住院。
- 高剂量铁剂使透析患者心衰住院减少44%。
核心结论
- CKD合并心衰患者预后差,且未充分从循证治疗中获益。
研究设计与样本
- 综述,讨论CKD中心衰的患病率及肾脏替代、器械和药物治疗证据。
主要发现
- β受体阻滞剂改善所有CKD分期HFrEF患者结局,包括透析患者。
- ACEI、ARB和MRA的研究排除了严重CKD患者(肌酐分别<2.5、<3.0、<2.5 mg/dl)。
- ARNI在eGFR低至20 ml/min/1.73 m2的随机试验中成功使用。
- SGLT2抑制剂改善HFrEF合并CKD 3-4期(eGFR>20 ml/min/1.73 m2)患者死亡和住院。
- 静脉铁改善心衰合并CKD 3期症状;高剂量铁使透析患者心衰住院减少44%。
关键数值与推荐
- ACEI研究入选肌酐<2.5 mg/dl,ARB<3.0 mg/dl,MRA<2.5 mg/dl。
- ARNI试验eGFR低至20 ml/min/1.73 m2。
- SGLT2抑制剂用于eGFR>20 ml/min/1.73 m2的CKD 3-4期。
- 高剂量铁剂降低透析患者心衰住院44%。
临床怎么用
- 合并CKD的心衰患者应接受循证药物和器械治疗,但需注意高钾血症和肾功能恶化风险。
- 高剂量和联合利尿剂常用于CKD 3-4期患者,但可能加重肾功能和电解质紊乱。
- 心脏-肾脏联合门诊和多学科方法可能改善HFrEF合并CKD患者的管理。
局限性
- ACEI、ARB和MRA的关键试验排除了严重CKD患者,证据外推受限。
- 对高钾血症和肾功能恶化的担忧导致RAAS抑制剂未在所有适用患者中使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CKD is common in patients with heart failure, associated with high mortality and morbidity, which is even higher in people undergoing long-term dialysis. Despite increasing use of evidence-based drug and device therapy in patients with heart failure in the general population, patients with CKD have not benefitted. This review discusses prevalence and evidence of kidney replacement, device, and drug therapies for heart failure in CKD. Evidence for treatment with β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and sodium-glucose cotransporter inhibitors in mild-to-moderate CKD has emerged from general population studies in patients with heart failure with reduced ejection fraction (HFrEF). β-Blockers have been shown to improve outcomes in patients with HFrEF in all stages of CKD, including patients on dialysis. However, studies of HFrEF selected patients with creatinine <2.5 mg/dl for ACE inhibitors, <3.0 mg/dl for angiotensin-receptor blockers, and <2.5 mg/dl for mineralocorticoid receptor antagonists, excluding patients with severe CKD. Angiotensin receptor neprilysin inhibitor therapy was successfully used in randomized trials in patients with eGFR as low as 20 ml/min per 1.73 m2 Hence, the benefits of renin-angiotensin-aldosterone axis inhibitor therapy in patients with mild-to-moderate CKD have been demonstrated, yet such therapy is not used in all suitable patients because of fear of hyperkalemia and worsening kidney function. Sodium-glucose cotransporter inhibitor therapy improved mortality and hospitalization in patients with HFrEF and CKD stages 3 and 4 (eGFR>20 ml/min per 1.73 m2). High-dose and combination diuretic therapy, often necessary, may be complicated with worsening kidney function and electrolyte imbalances, but has been used successfully in patients with CKD stages 3 and 4. Intravenous iron improved symptoms in patients with heart failure and CKD stage 3; and high-dose iron reduced heart failure hospitalizations by 44% in patients on dialysis. Cardiac resynchronization therapy reduced death and hospitalizations in patients with heart failure and CKD stage 3. Peritoneal dialysis in patients with symptomatic fluid overload improved symptoms and prevented hospital admissions. Evidence suggests that combined cardiology-nephrology clinics may help improve management of patients with HFrEF and CKD. A multidisciplinary approach may be necessary for implementation of evidence-based therapy.
引用
- Banerjee D, Rosano G, Herzog CA, et al. Management of Heart Failure Patient with CKD. Clin J Am Soc Nephrol. 2021. PMID: 33495289. doi:10.2215/CJN.14180920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。